合成异醇衍生物作为潜在的抗癌药物,特别是对于卵巢癌:体外细胞毒性,细胞循环停止,网络药理学和分子对接研究
Yuxin Ding1, Enxiao Wang1, Lin Xing1
1College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Bioorganic & medicinal chemistry letters
|May 1, 2025
概括
我们合成了新型异骨醇衍生物来增强抗瘤特性. 衍生品10在多个癌症细胞系中表现出显著的抗增殖活性,显示出作为抗癌药物候选药物的潜力.
科学领域:
- 自然产品 化学 化学
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 伊索斯泰维醇是一种四环双类药物,具有中度的抗瘤作用.
- 在C-16和C-19位置的修改可能会提高异维醇的疗效.
研究的目的:
- 合成和评估新型异醇衍生物,以增强抗癌活性.
- 调查这些衍生品的结构-活性关系 (SARs).
- 探索最活跃衍生品的作用机制和潜在目标.
主要方法:
- 合成和鉴定异醇衍生物的特征 (2-17).
- 在HCT116,SKOV3和HepG2癌细胞系中使用CCK-8试验进行体外抗增殖活性评估.
- 细胞周期分析和亡诱导研究.
- 网络药理学用于目标预测和分子对接分析.
主要成果:
- 衍生品10对HCT116,SKOV3和HepG2细胞表现出强烈的抗增殖活性 (IC50值在23.09至26.15μM之间).
- 衍生品10诱导S-G2/M阶段细胞周期停止和SKOV3细胞的细胞亡.
- 网络药理学和分子对接确定HSP90AA1为衍生品10的潜在目标,具有显著的对接能量 (-8.96 kcal/mol).
结论:
- 衍生品10代表了一种有前途的化合物用于抗癌药物开发.
- 在C-16和C-19位置的修改显著提高了异骨醇的抗瘤功效.
- 对衍生品10与HSP90AA1的相互作用进行进一步的研究对于卵巢癌治疗是有必要的.
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K